Molecule
Dextrose is a prescription medicine indicated as source of water and calories in adult and pediatric patients, and may also be used as a diluent for reconstitution of a powder or liquid drug product. MedsAcross supplies Dextrose for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Dextrose Injection (5% and 10%) is indicated as source of water and calories in adult and pediatric patients, and may also be used as a diluent for reconstitution of a powder or liquid drug product. Dextrose Injection (5% and 10%) is indicated as a source of water and calories in adults and pediatric patients, and may also be used as a diluent for reconstitution of a powder or liquid drug product.
Source: US FDA prescribing information
Dextrose provides a source of carbohydrate calories and is used to supplement nutrition by providing glucose parenterally.
Source: US FDA prescribing information
• Only for intravenous infusion. • Infusion rate depends on the age, weight, clinical and metabolic conditions of the patient and concomitant therapy. See full prescribing information for information on preparation, administration, dosing considerations.
Source: US FDA prescribing information
Dextrose Injection (5% and 10%) is contraindicated in patients with: • Clinically significant hyperglycemia. • Known hypersensitivity to dextrose. • Clinically significant hyperglycemia. • Known hypersensitivity to dextrose.
Source: US FDA prescribing information
• Neonatal Hypoglycemia: Closely monitor blood glucose concentrations to ensure adequate glycemic control. • Hyperglycemia or Hyperosmolar Hyperglycemic State: Use with caution in patients with known subclinical or overt diabetes mellitus. • Hypersensitivity Reactions: Monitor for signs and symptoms and discontinue infusion immediately if reactions occur. • Phlebitis and Thrombosis: Remove catheter as soon as possible if thrombophlebitis develops. • Hyponatremia: Monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and neurologic status. • Electrolyte Imbalance and Fluid Overload: Monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during administration. • Refeeding Syndrome: Monitor laboratory parameters.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: • Neonatal Hypoglycemia • Hyperglycemia and Hyperosmolar Hyperglycemic State • Hypersensitivity Reactions • Phlebitis and Thrombosis • Hyponatremia • Electrolyte Imbalance and Fluid overload • Refeeding syndrome The following adverse reactions associated with the use of dextrose injection were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.
Source: US FDA prescribing information
Effects on Glycemic Control and Electrolyte Balance: Monitor blood glucose concentrations, fluid balance, serum electrolyte concentrations and acid-base balance. Avoid use of Dextrose Injection in patients receiving drugs associated with hyponatremia.
Source: US FDA prescribing information
It is recommended the product be stored at room temperature (25°C/77°F), brief exposure up to 40°C/104°F does not adversely affect the product.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
19 presentations of Dextrose, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Dextrose 5 g/100 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 2.5 g/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 25 g/50 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 25000 mg/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 12500 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 50 g/1000 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 25000 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 50 g/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 100 g/1000 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 2500 mg/10 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 1.25 g/25 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 1400 g/2000 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 100 g/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 150 g/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 200 g/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 250 g/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 350 g/500 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Dextrose 7.5 g/150 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Infant Dextrose 2500 mg/10 mL injectionIntravenous | Henry Schein | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 25 January 1971 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Dextrose in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 19 presentations of Dextrose and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Dextrose, including Infant Dextrose.
Yes. The US FDA first approved Dextrose on 25 January 1971, according to Drugs@FDA.
No listed presentation of Dextrose is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Dextrose is classified under ATC code B05CX01 (Dextrose).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.